company background image
THTX logo

Theratechnologies NasdaqCM:THTX Stock Report

Last Price

US$2.00

Market Cap

US$95.6m

7D

10.2%

1Y

-4.5%

Updated

08 Jan, 2025

Data

Company Financials +

Theratechnologies Inc.

NasdaqCM:THTX Stock Report

Market Cap: US$95.6m

THTX Stock Overview

A biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. More details

THTX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Theratechnologies Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Theratechnologies
Historical stock prices
Current Share PriceCA$2.00
52 Week HighCA$2.27
52 Week LowCA$1.08
Beta1.54
1 Month Change28.71%
3 Month Change57.73%
1 Year Change-4.55%
3 Year Change-82.80%
5 Year Change-83.70%
Change since IPO-89.61%

Recent News & Updates

Recent updates

Shareholder Returns

THTXUS BiotechsUS Market
7D10.2%1.2%0.7%
1Y-4.5%-7.0%23.0%

Return vs Industry: THTX exceeded the US Biotechs industry which returned -6.6% over the past year.

Return vs Market: THTX underperformed the US Market which returned 23.9% over the past year.

Price Volatility

Is THTX's price volatile compared to industry and market?
THTX volatility
THTX Average Weekly Movement8.9%
Biotechs Industry Average Movement11.1%
Market Average Movement6.4%
10% most volatile stocks in US Market18.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: THTX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: THTX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1993103Paul Lévesquewww.theratech.com

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers.

Theratechnologies Inc. Fundamentals Summary

How do Theratechnologies's earnings and revenue compare to its market cap?
THTX fundamental statistics
Market capUS$95.59m
Earnings (TTM)-US$3.16m
Revenue (TTM)US$84.32m

1.1x

P/S Ratio

-29.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
THTX income statement (TTM)
RevenueUS$84.32m
Cost of RevenueUS$19.42m
Gross ProfitUS$64.90m
Other ExpensesUS$68.06m
Earnings-US$3.16m

Last Reported Earnings

Aug 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.069
Gross Margin76.97%
Net Profit Margin-3.75%
Debt/Equity Ratio-290.4%

How did THTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 05:05
End of Day Share Price 2025/01/08 00:00
Earnings2024/08/31
Annual Earnings2023/11/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Theratechnologies Inc. is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZhangBMO Capital Markets U.S. (Historical)
Douglas LoeByron Capital Markets
Dewey SteadmanCanaccord Genuity